New combo aims to stop liver cancer from coming back
Disease control
Not yet recruiting
This phase II trial tests whether giving the immunotherapy drug sintilimab along with targeted radiation before surgery can lower the risk of liver cancer returning. About 110 patients with resectable liver cancer will be randomly assigned to receive the combination therapy befor…
Phase: PHASE2 • Sponsor: Lei ZHAO • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC